Methylprednisolone in Bilayer Liposomes Prolongs Cardiac and Renal Allograft Survival, Inhibits Macrophage Activation, and Selectively Modifies Antigen Presentation and T-Helper Cell Function in Rat Recipients

Binder, Jochen; Braeutigam, R; Oertl, Anton; Kramer, W.; Jonas, Dietger; Hancock, Wayne W.; Kupiec‐Weglinski, Jerzy W.

doi:10.1016/s0041-1345(98)00147-x

Cited by 4 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, selective delivery of glucocorticoids to the immune system, such as the liver and spleen, would be advantageous for improving the efficacy and reducing side effects of these drugs in organ transplantation. Indeed, studies6,7 using liposomal formulations of MP have shown that enhanced delivery of the steroid to the spleen would result in an improved survival rate in experimental organ transplantation.…”

Section: Introductionmentioning

confidence: 99%

Dextran–methylprednisolone succinate as a prodrug of methylprednisolone: Plasma and tissue disposition**A preliminary account of this study was presented at the Twelfth Annual Meeting of the American Association of Pharmaceutical Sciences, Boston, MA, November 2–6, 1997 (Mehvar R. 1997. Targeted delivery of methylprednisolone using a dextran prodrug. Pharm Res 14:S336).

Zhang

Mehvar

2001

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Dextran–methylprednisolone succinate as a prodrug of methylprednisolone: Plasma and tissue disposition**A preliminary account of this study was presented at the Twelfth Annual Meeting of the American Association of Pharmaceutical Sciences, Boston, MA, November 2–6, 1997 (Mehvar R. 1997. Targeted delivery of methylprednisolone using a dextran prodrug. Pharm Res 14:S336).

Zhang

Mehvar

2001

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Compared to free methylprednisolong, liposome encapsulated methylprednisolone may be selectively inhibited T-cell activation and cytokine production. The expression of CD45RC, CD25, IL-2, IL-7, IL12, TNF-α, INF-γ was strongly inhibited in drug encapsulated group49.…”

Section: Application Of Nanotechnology For Treatmentmentioning

confidence: 89%

Nanotechnology in Urology

Jin

Labhasetwar

2009

Urologic Clinics of North America

View full text Add to dashboard Cite

Nanomedicine is a new distinct scientific discipline that explores applications of nanoscale materials (1-1000 nm) for various biomedical applications. At nanoscale, the physical properties of materials are altered as well as their interactions with cells and tissue. This occurs primarily because of the significant difference in the surface area-volume ratio as materials are reduced to nanosized level 1 . Nanomedicine explores nanotechnology for monitoring, repair, and control of human biological systems at cellular and molecular levels using engineered nanodevices and nanostructures 2 . Nanomedicine thus can improve diagnosis and treatment, and it can also be used in tissue engineering to replace some functions of human organs. The potential scope of nanotechnology in urology is wide-ranging, from prevention to early detection, treatment, prognosis, and symptom management 3 . The most common nanoscale drug delivery and imaging vehicles (nanocarriers) include polymeric nanoparticle, dendrimers, nanoshells, liposomes, nucleic acid based nanoparticles, magnetic nanoparticle, and virus nanoparticles 4 . This review summarizes some of the emerging applications of nanomedicine in urology.

show abstract

“…Liposomes have been explored in this field for quite some time in order to reduce adverse effects and increase drug efficacy. This started with liposomal encapsulation of standard-of-care drugs such as cyclosporine and methylprednisolone, where increased efficacy was reported in rat models of liver, cardiac, and renal transplantation, respectively [ 178 , 179 , 180 ]. Innovations in the field of liposomal therapy include gene therapy to increase graft survival, targeted drug delivery to treat rejection, and a combination of liposomal immunosuppressants to increase cell engraftment.…”

Section: Application In Inflammatory Diseasementioning

confidence: 99%

Recent Advances in Liposomal-Based Anti-Inflammatory Therapy

et al. 2021

View full text Add to dashboard Cite

Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to (passively) target sites of inflammation and release their content to inflammatory target cells enables them to increase local efficacy with only limited systemic exposure and adverse effects. Nonetheless, few liposomal formulations seem to reach the clinic. The current review provides an overview of the more recent innovations in liposomal treatment of rheumatoid arthritis, psoriasis, vascular inflammation, and transplantation. Cutting edge developments include the liposomal delivery of gene and RNA therapeutics and the use of hybrid systems where several liposomal bilayer features, or several drugs, are combined in a single formulation. The majority of the articles reviewed here focus on preclinical animal studies where proof-of-principle of an improved efficacy–safety ratio is observed when using liposomal formulations. A few clinical studies are included as well, which brings us to a discussion about the challenges of clinical translation of liposomal nanomedicines in the field of inflammatory diseases.

show abstract

Methylprednisolone in Bilayer Liposomes Prolongs Cardiac and Renal Allograft Survival, Inhibits Macrophage Activation, and Selectively Modifies Antigen Presentation and T-Helper Cell Function in Rat Recipients

Cited by 4 publications

References 1 publication

Nanotechnology in Urology

Recent Advances in Liposomal-Based Anti-Inflammatory Therapy

Contact Info

Product

Resources

About